Your browser doesn't support javascript.
loading
Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group.
Mulder, Renée L; Font-Gonzalez, Anna; Green, Daniel M; Loeffen, Erik A H; Hudson, Melissa M; Loonen, Jacqueline; Yu, Richard; Ginsberg, Jill P; Mitchell, Rod T; Byrne, Julianne; Skinner, Roderick; Anazodo, Antoinette; Constine, Louis S; de Vries, Andrica; Jahnukainen, Kirsi; Lorenzo, Armando; Meissner, Andreas; Nahata, Leena; Dinkelman-Smit, Marij; Tournaye, Herman; Haupt, Riccardo; van den Heuvel-Eibrink, Marry M; van Santen, Hanneke M; van Pelt, Ans M M; Dirksen, Uta; den Hartogh, Jaap; van Dulmen-den Broeder, Eline; Wallace, W Hamish; Levine, Jennifer; Tissing, Wim J E; Kremer, Leontien C M; Kenney, Lisa B; van de Wetering, Marianne D.
Afiliação
  • Mulder RL; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands. Electronic address: r.l.mulder@prinsesmaximacentrum.nl.
  • Font-Gonzalez A; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Amsterdam University, Amsterdam UMC, location AMC, Amsterdam, Netherlands.
  • Green DM; Department of Epidemiology and Cancer Control and Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Loeffen EAH; Department of Pediatric Oncology/Hematology, Beatrix Children's Hospital, UMC Groningen, University of Groningen, Groningen, Netherlands.
  • Hudson MM; Department of Epidemiology and Cancer Control and Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Loonen J; Department of Hematology, Radboudumc, Nijmegen, Netherlands.
  • Yu R; Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Harvard Universty, Boston, MA, USA.
  • Ginsberg JP; Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA, USA.
  • Mitchell RT; Medical Research Council Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK.
  • Byrne J; Boyne Research Institute, Drogheda, Ireland.
  • Skinner R; Department of Paediatric and Adolescent Haematology/Oncology, Great North Children's Hospital, Newcastle upon Tyne, UK; Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.
  • Anazodo A; Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia; Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW, Australia; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.
  • Constine LS; Department of Radiation Oncology and Department of Pediatrics, University of Rochester Medical Center, University of Rochester, NY, USA.
  • de Vries A; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands.
  • Jahnukainen K; Children's Hospital, University of Helsinki, Helsinki, Finland; Helsinki University Central Hospital, Helsinki, Finland.
  • Lorenzo A; Division of Urology, Hospital for Sick Children, Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Meissner A; Center for Reproductive Medicine, Amsterdam UMC, location AMC, Amsterdam, Netherlands; Department of Urology, Amsterdam UMC, location AMC, Amsterdam, Netherlands.
  • Nahata L; Division of Endocrinology, Nationwide Children's Hospital, Columbus, OH, USA; Department of Pediatrics, The Ohio State University College of Medicine, The Ohio State University, Columbus, OH, USA.
  • Dinkelman-Smit M; Division of Andrology, Department of Urology, Erasmus MC, Rotterdam, Netherlands.
  • Tournaye H; Centre for Reproductive Medicine, Free University of Brussels, Brussels, Belgium.
  • Haupt R; Epidemiology and Biostatistics Unit and Livebirth Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands.
  • van Santen HM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, UMC Utrecht, Utrecht, Netherlands.
  • van Pelt AMM; Laboratory for Reproductive Biology, Amsterdam UMC, location AMC, Amsterdam, Netherlands.
  • Dirksen U; Department of Pediatrics III, West German Cancer Centre, Essen University Hospital, Essen, Germany; German Cancer Consortium (DKTK) Partner Site, Essen, Germany.
  • den Hartogh J; Dutch Childhood Cancer Parent Organization (VOX), Nieuwegein, Netherlands.
  • van Dulmen-den Broeder E; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Wallace WH; Department of Paediatric Haematology and Oncology, Royal Hospital for Sick Children, Edinburgh, UK.
  • Levine J; Division of Pediatric Hematology and Oncology, Weill Cornell Medicine, Cornell University, New York, NY, USA.
  • Tissing WJE; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology/Hematology, Beatrix Children's Hospital, UMC Groningen, University of Groningen, Groningen, Netherlands.
  • Kremer LCM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Pediatric Oncology, Emma Children's Hospital, Amsterdam University, Amsterdam UMC, location AMC, Amsterdam, Netherlands.
  • Kenney LB; Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Harvard Universty, Boston, MA, USA.
  • van de Wetering MD; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Lancet Oncol ; 22(2): e57-e67, 2021 02.
Article em En | MEDLINE | ID: mdl-33539754
ABSTRACT
Male patients with childhood, adolescent, and young adult cancer are at an increased risk for infertility if their treatment adversely affects reproductive organ function. Future fertility is a primary concern of patients and their families. Variations in clinical practice are barriers to the timely implementation of interventions that preserve fertility. As part of the PanCareLIFE Consortium, in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in male patients who are diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. Recognising the need for global consensus, this clinical practice guideline used existing evidence and international expertise to rigorously develop transparent recommendations that are easy to use to facilitate the care of male patients with childhood, adolescent, and young adult cancer who are at high risk of fertility impairment and to enhance their quality of life.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Preservação da Fertilidade / Neoplasias Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Limite: Adolescent / Adult / Child / Humans / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Preservação da Fertilidade / Neoplasias Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Limite: Adolescent / Adult / Child / Humans / Male Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article